<DOC>
	<DOCNO>NCT02303600</DOCNO>
	<brief_summary>Cough common symptom respiratory medicine clinic patient , complex etiology wide-ranging . Cough usually divide three category time : acute cough , subacute cough chronic cough . Subacute 3~8 week course disease . Its main etiology postinfectious cough , mostly secondary viral infection.Considering overexpression postinfectious patient , Cysteinyl leukotriene ( CysLTs ) play role gathering eosinophils respiratory . The level FENO significant correlation inflammatory airway eosinophils . While CysLTs overexpressed vivo , level FENO may increase . Montelukast , CysLTs-receptor-1 antagonists， play role control airway inflammation decrease airway high activity suppress biological activity CysLTs . It effective theory therapy sub-acute cough Montelukast , short course relieve cough symptom soon possible . The aim research whether FENO use biomarker optimize treatment regimen sub-acute cough .</brief_summary>
	<brief_title>Fractional Concentration Exhaled NO ( FENO ) Direct Montelukast Treatment Sub-acute Cough</brief_title>
	<detailed_description>This project prospective , open label , randomize control trial . All subacute cough patient meet inclusion/exclusion criterion recruit sign consent form . Patients randomized biomarker treatment arm standard treatment arm . Positive negative biomarker expression confirm assess fractional concentration exhale NO ( FENO ) level , FENO＜25ppb regard negative FENO≥25ppb regard positive . Patients biomarker guide positive treatment arm give Montelukast Sodium Tablets ( p.o. , 10mg , q.d . ) . Patients biomarker guide negative treatment arm give placebo tablet ( p.o. , 10mg , q.d. ) . Patients standard treatment arm give Montelukast Sodium Tablets ( p.o. , 10mg , q.d . ) .All treatment regimen last 10 day antitussive/decongestant bronchodilator give patient . Examine result patient arm record 10 day treatment . The examine record FENO level , cough symptom assessment , cough visual assessment , Leicester cough questionnaire , total white blood cell count , neutrophil blood percentage , eosinophil blood percentage . Patient cough free day treatment Montelukast Sodium Tablets . Follow carry 8th week first record symptom 2 month treatment .</detailed_description>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Cough main clinical symptom persistent 38 week Chest Xray reveals noticeable pathological change ≥18 year old , regardless gender ethical background Not take angiotensinconverting enzyme inhibitor Patients must join programme voluntarily able attend examination followup session Patients diagnose rhinallergosis , chronic nasosinusitis bacterial respiratory tract infection Patients diagnose severe reportorial disease severe systemic disease Patients allergic drug test Patients noncooperative examination session step trial Patients able refuse sign consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Sub-acute cough</keyword>
</DOC>